Amplifying Evidence with Unified Clinical Trial Data Collection

Musaddiq Khan, VP, Therapeutic Area Solutions Leader, Medable

Musaddiq Khan (“Muz”) has been involved in clinical research for over 17 years. Most recently, he was the Director of Clinical Program Operations in the Exploratory Medicine & Pharmacology group at Eli Lilly, where he led the operational delivery of the first-in-human study on Lilly’s COVID-19 Antibody program. Throughout his career, Muz has held various clinical operations roles in pharma, including Parexel, Roche and AstraZeneca. Muz completed his Executive MBA from the University of Cambridge with a dissertation on “Developing a Digital Health Strategy for Early Clinical Development.”

Cindy Howry, VP, eCOA Science, Medable

Cindy Howry is a nationally recognized thought-leader in the area of electronic Clinical Outcome Assessments (eCOA) and digital physiological measures which empowers the patient and engages them to maintain and improve their health, simultaneously enabling clinical teams to have real-time access to better quality clinical data.  Ms. Howry has more than 35 years of experience in management and leadership, including 21 years in clinical research.

She is Vice-President, eCOA Science at Medable. Previously, she was CEO for assisTek, a leading-edge company providing eSource solutions for healthcare and clinical research; in addition, she is served three terms in the elected position of Vice-Director for ePRO Consortium at C-PATH, a group of eCOA companies working in a non-competitive environment to advance the quality, practicality, and acceptability of electronic data capture (EDC) methods used in clinical trials for PRO endpoint assessment.

Sarah Valentine, Partnerships Lead, Life Sciences, Digital Medicine Society (DiMe)

Sarah Valentine leads partnerships across life sciences at the Digital Medicine Society (DiMe). In her role, she thinks critically about the challenges we face in drug development and commercialization to drive strategy, prioritization, and concept development across areas of unmet need where there’s an opportunity at the intersection of healthcare and technology to deliver unprecedented value to patients and other stakeholders across our industry. She convenes teams of interdisciplinary thought leaders and subject matter experts to tackle some of the biggest challenges we face as a field in order to advance the ethical, effective, equitable, and safe use of digital medicine to redefine healthcare and improve lives. Prior to her role at DiMe, Sarah was a digital implementation lead at Eli Lilly & Company, where she led efforts at the intersection of clinical development and digital health to leverage innovative digital technologies and capabilities including digital measures, combination products, and other DDTs in clinical research.